BETA2,086.00

Beta Drugs Limited

· Unclassified
₹ CrorePeersTHEJOMACPOWERSAKARSERVOTECHMcap ₹2,115 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
BETA
FY26
GAJA
no data
THEJO
FY26
MACPOWER
FY26
Peer
Median
Valuation — at last close
P/E50.98×48.45×55.14×51.79× -2%
P/B8.64×6.30×10.66×8.48× +2%
EV/EBITDA28.24×29.43×34.50×31.96× -12%
Market Cap₹2,115 Cr₹2,386 Cr₹1,868 Cr₹2,127 Cr -1%
Growth
Revenue CAGR 3Y18.17%18.17%
Revenue CAGR 5Y24.17%24.17%
Net Income CAGR 3Y37.99%37.99%
Revenue YoY (latest Q)31.02%56.06%43.54%
Net Income YoY (latest Q)56.10%110.33%83.22%
Profitability
EBITDA Margin19.67%12.67%16.20%14.43% +36%
Net Income Margin10.78%7.73%10.17%8.95% +20%
Return on Common Equity16.95%13.00%19.33%16.16% +5%
Return on Capital Employed15.10%15.66%26.09%20.88% -28%
Return on Assets8.37%8.90%12.76%10.83% -23%
Credit & Quality
Total Debt/Equity0.60×0.01×0.00×0.01× +11900%
Interest Coverage3.82×12.37×29.74×21.05× -82%
Scale — latest FY
Revenue / Total Income₹385 Cr₹632 Cr₹333 Cr₹483 Cr -20%
Net Income₹41.5 Cr₹48.8 Cr₹33.9 Cr₹41.4 Cr +0%
Total Assets₹496 Cr₹549 Cr₹265 Cr₹407 Cr +22%
EPS₹40.92₹45.41₹33.86₹39.64 +3%
Book Value per Share₹241.47₹349.34₹175.17₹262.26 -8%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.